Experimental evaluation of inflammatory process in the prostate caused by transurethral transmission of uropathogen in low counts


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. According to the literature, bacterial count of uropathogens isolated from expressed prostate secretion and urine which is sufficient for a diagnosis of bacterial prostatitis I and II categories, remains contradictory. Undoubtedly, the identification ofmicroorganisms from affected organ in high titers indicates the presence of a relevant infectious-inflammatory process. In turn, there is no consensus on the development of bacterial prostatitis at lower titers of uropathogens. Thus, the aim of our study was to identify and compare the potential features of the development and occurrence of an infectious inflammatory process in the prostate during the reproduction of bacterial prostatitis in an animal model using a low titer of causative uropathogens. Materials and methods. A total of 16 «New Zealand» mature male rabbits aged 24±2 weeks old with weight of 3.5+0.3 kg were examined. Inoculation was performed via transurethral route, according to the developed experimental technique. E. coli was used as bacterial agent with a count of 1 x 103 CFU/ml, 1 x 105 CFU/ml and 1 x 107 CFU/ml. All animals were randomized into 4 groups of 4 individuals depending on the titer of the inoculated microorganisms (groups 1-3, respectively), group 4 - control (with inoculation by Sol. NaCl 0.9%). Sacrification and vivisection were performed on days 1, 3, 7 and 14 of the control days. Biopsy specimens from the lower urinary tract and internal genital organs of laboratory animals (bladder, urethra, prostatic complex - 6 biopsies #1A-1D, 2A, 2B) were evaluated morphologically and bacteriologically. Analytical evaluation of the experimental data was presented using descriptive statistical methods. Results. In experimental groups (Groups 1-3), bacteriological examination of prostatic complex biopsies showed growth of microflora in all samples in titers of 10x-107 CFU / ml. In group 1, the maximum concentration of uropathogen was observed on day 7, compared to day 1 in both groups 2 and 3. In all observed cases, the highest degree of bacterial contamination was noted in the biopsy specimens from paraprostatic tissues and distal part of the prostate, which was 4.0+1.7 lg CFU/ml and 3.5+1.9 lg CFU/ml, respectively, and the smallest in proximal prostatic loci (1C) and bladder neck (2B) - 3.0+1.2 lg COE / ml and 3.0+1.7 lg COE / ml, respectively. According to the morphological study, a relevant progression of the suppurative and destructive inflammation (with foci of colliquation necrosis) was identified in group 1 in the biopsies from the prostate with a maximum degree of changes on day 7 with subsequent formation of loose connective tissue proliferation areas by 14 days. This indicates the conversion of the inflammatory process to the chronic stage. These changes corresponded with the results of histopathological studies in groups 2 and 3 where higher titers of bacterial agent were used. In group 4 (control) the commensal flora was bacteriologically determined in the biopsies, but there were no signs of inflammation, according to the results of the morphological study. Conclusion. In experimental model, we found that E. coli 103 CFU / ml induces the development of a phasic inflammatory process in the structures of the prostatic complex. These processes resulted in the formation of irreversible proliferative changes. As a consequence, it shold be recommended to consider these signs of contamination when evaluating the results of bacteriological examination of expressed prostate secretion/urine samples during planning treatment strategy.

Full Text

Restricted Access

About the authors

M. I Kogan

FGBOU VO Rostov State Medical University of Russian Federation Ministry of Health

Email: dept_kogan@mail.ru

Yu. L Naboka

FGBOU VO Rostov State Medical University of Russian Federation Ministry of Health

Email: nagu22@mail.ru

S. S. Todorov

FGBOU VO Rostov State Medical University of Russian Federation Ministry of Health

Email: sertodorov@gmail.com

R. S Ismailov

FGBOU VO Rostov State Medical University of Russian Federation Ministry of Health

Email: dr.ruslan.ismaiIov@gmaiI.com
Full-time Ph.D. student at the Department of Urology and Human Reproductive Health with the Course of Pediatric Urology-andrology of the Advanced Training and Specialist Professional Retraining Faculty

References

  1. Bonkat G, Bartoletti R.R., Bruyere F., Cai T, Geerlings S.E., Koves B., Schubert S., Wagenlehner F. Guidelines on Urological Infections. European Association of Urology. Edn. Presented at the EAU Annual Congress Barcelona 2019. ISBN 978-94-92671-04-2.
  2. Nickel J.C., Shoskes D., Wang Y, Alexander R.B., Fowler J.E. Jr, Zeitlin S., O’Leary M.P., Pontari M.A., Schaeffer A.J., Landis J.R., Nyberg L, Kusek J.W., Propert K.J. How does the pre-massage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis/chronic pelvic pain syndrome? J Urol. 2006;176(1):119-124. doi: 10.1016/S0022-5347(06)00498-8.
  3. Coker T.J., Dierfeldt D.M. Acute bacterial prostatitis. Diagnosis and management: a systematic review. Ehr Berg Fam Med Res Prog. 2016;3(2):114-120. PMID: 26926407.
  4. Nickel J.C. CUA Guideline on Prostatitis. Can UrolAssoc J. 2011;5(5):306- 315. doi: 10.5489/cuaj.11211.
  5. Stamatiou K., Karageorgopoulos D.E. A prospective observational study of chronic prostatitis with emphasis on epidemiological and microbiological features. Urologia. 2013;80(3):225-232. doi: 10.5301/urologia.5000024.
  6. Roberts R.O., Lieber M.M., Bostwick D.G., Jacobsen S.J. A review of clinical and pathological prostatitis syndromes. Urology. 1997;49(6):809-821. PMID: 9187684
  7. Schaeffer A. Weidner W., Barbalias G.A., Bottod H, Bjerklund Johansen T.E., Hochreiter W.W., Krieger J.N., LobelB., NaberK.G., Nickel J.C., Potts J.M., T enke P., Hart C. Summary consensus statement: diagnosis and management of chronic prostatitis. Chronic Pelvic Pain Syndrom. Europ. Urol. (Suppl.). 2003;(2):1-4. doi: 10.1016/S1569-9056(02)00191-4.
  8. Набер К.Г., Сухорукова М.В. Микробиологические аспекты диагностики хронического простатита. Клиническая микробиология и антимикробная химиотерапия. 2006; 8(1):4-17
  9. Zegarra Montes L.Z., Sanchez Mejia A.A., LozaMunarriz C.A., Gutierrez E.C. Semen and urine culture in the diagnosis of chronic bacterial prostatitis. IntBraz J Urol. 2008;34(1):30-37. PMID: 18341719
  10. Naber K.G. Management of bacterial prostatitis: what’s new? BJU Int. 2008;101(Suppl 3):7-10. doi: 10.1111/j.1464-410X.2008.07495.x
  11. Sutcliffe S., Platz E.A. Inflammation and prostate cancer: a focus on infections. Curr Urol Rep 2008;9: 243-249. PMID: 18765120.
  12. Nickel J.C. Inflammation and benign prostatic hyperplasia. UrolClin North Am 2008;35:109-115 doi: 10.1016/j.ucl.2007.09.012.
  13. Guo-Dong Qin, Ming-Zhao Xiao, Yuan-Da Zhou, Jing Yang, Hai-Xia He, Yue He, Yang Zeng. Tamsulosin alters levofloxacin pharmacokinetics in prostates derived from rats with acute bacterial prostatitis. Asian J Androl. 2013;15(2):254-260. doi: 10.1038/aja.2012.134
  14. Fan L., Shang X., Zhu J., Ma B., Zhang Q. Pharmacodynamic and pharmacokinetic studies and prostatic tissue distribution of fosfomycintromethamine in bacterial prostatitis or normal rats. Andrologia. 2018;50(6):e13021. doi: 10.1111/and.13021.
  15. Hooijmans C.R., Leenaars M., Ritskes-Hoitinga M. A gold standard publication checklist to improve the quality of animal studies, to fully integrate the Three Rs, and to make systematic reviews more feasible. Altern Lab Anim. 2010;38(2):167-182. doi: 10.1177/026119291003800208.
  16. Kilkenny C., Browne W.J., Cuthill I.C. Emerson M., Altman D.G. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8(6):e1000412. doi: 10.1371/journal.pbio.1000412.
  17. Александров И.В., Егорова Е.И., Васина Е.Ю., Новиков В.К., Матыко П.Г., Галагудза М.М. Экспериментальные исследования на животных в эпоху трансляционной медицины. Какими им быть? Трансляционная медицина. 2017; 4(2): 52-70
  18. Директива 2010/63/EU Европейского парламента и Совета Европейского Союза от 22 сентября 2010 года по охране животных, используемых в научных целях, соответствующей требованиям Европейской экономической зоны .OJ L. 2010: 276: 33-79
  19. Хельсинкская декларация всемирной медицинской ассоциации. Этические принципы проведения медицинских исследований с участием человека в качестве субъекта. Принята на 18-й Генеральной aссамблее ВМА, Хельсинки, Финляндия, июнь 1964 г., последние изменения внесены на 64-й Генеральной aссамблее ВМА, Форталеза, Бразилия, октябрь 2013 г. JAMA. 2013;310(20): 2191-2194
  20. Европейская конвенция о защите позвоночных животных, используемых в экспериментальных и иных научных целях (ETS № 123). Приложение А «Руководство по содержанию и уходу за животными». Приняты: Страсбург, 18.03.1986, вступили в силу: 01.01.1991. Источник: https://rm.coe.int/ CoERMPublicCommonSearchServices/DisplayDCTMContent?documentI d=090000168007a67b
  21. FELASA recommendations for the health monitoring of mouse, rat, hamster, guinea pig and rabbit colonies in breeding and experimental units. Mahler M., Berard M., Feinstein R., Gallagher A., Illgen-Wilcke B., Pritchett-Corning K., Raspa M. Laboratory Animals. 2014;48(3); 178-192. doi: 10.1177/0023677213516312. 22. Guidelines for accommodation and care of animals. Environment, housing and management. Adopted: 2017-01-06
  22. ГОСТ 33215-2014. Руководство по содержанию и уходу за лабораторными животными. Правила оборудования помещений и организации процедур. Введ. 2017-01-06. М.: Стандартинформ, 2016. 20 с
  23. ГОСТ 33216, 2014. Руководство по содержанию и уходу за лабораторными животными. Правила содержания и ухода за лабораторными грызунами и кроликами. Введ. 2016-07-01. М.: Стандартинформ, 2016. 22 с
  24. Патент РФ RU 2452774 C1 № 2011103414/10 от 31.01.2011. Способ определения бактериологической обсеменённости мочи, секрета предстательной железы и эякулята. Набока Ю.Л., Коган М.И., Гудима И.А., Мирошниченко Е.А., Ибишев Х.С., Брагина Л.Е., Ферзаули А.Х., Джалагония О.Т. Заявитель и патентообладатель: Набока Ю.Л., Коган М.И. Опубл. 10.06.2012. Бюл. № 16. 12 с
  25. Butterworth-Heinemann. Text book of Rabbit Medicine. Reed Educ. and Prof. Publ. Ltd. Alden Press, Oxford, United Kingdom. 2002.
  26. Domingue G.J. Sr., Hellstrom W.J.G. Prostatitis. Clin Microbiol Rev. 1998;11(4):604-613.
  27. Nickel J.C., Olson M.E., Barabas A., Benediktsson H., Dasgupta M.K., Costerton J.W. Pathogenesis of Chronic Bacterial Prostatitis in an animal model. British J Urol. 1990;66(6):47-54. Doi: 10.1111/j. 1464-410X. 1990. tb14864.x/
  28. Lee Y.S., Han C.H., Kang S.H., Lee S.-J., Kim S.W, Shin O.R., Sim Y.-C, Lee S.-J., Cho Y.-H. Synergistic effect between catechin and ciprofloxacin on chronic bacterial prostatitis rat model. Int J Urol. 2005;12:383-389. doi: 10.1111/j.1442-2042.2005.01052.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies